- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00534807
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
August 31, 2015 updated by: Bristol-Myers Squibb
Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer
The purpose of this study is to test how vinflunine interacts with rifampin in the human body
Study Overview
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cancer unresponsive to previous treatment
- Consent for genetic samples
Exclusion Criteria:
- Cancer of the blood
- Spread of cancer to the brain
- Moderate or severe nerve damage
- Low white blood cell counts and platelet counts
- Inadequate liver or kidney function
- Prior treatment with vinflunine
- Use of certain medications that might interfere with the metabolism of vinflunine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Primary Outcome Measure of the effect of rifampin on the pharmacokinetics (PK) of intravenous (IV) vinflunine will be determined from the PK measurements
Time Frame: taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment
|
taken during Cycle 2 of study treatment, at approximately 4 weeks after the start of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Secondary Outcome Measures of the safety and tolerability of vinflunine when administered alone and with rifampin
Time Frame: determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment
|
determined after 2 complete 21-day Cycles of study treatment, at approximately 6 weeks after the start of study treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (ANTICIPATED)
November 1, 2008
Study Completion (ANTICIPATED)
November 1, 2008
Study Registration Dates
First Submitted
September 25, 2007
First Submitted That Met QC Criteria
September 25, 2007
First Posted (ESTIMATE)
September 26, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
September 1, 2015
Last Update Submitted That Met QC Criteria
August 31, 2015
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
Other Study ID Numbers
- CA183-033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States
Clinical Trials on Rifampin
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR)Active, not recruitingLatent TuberculosisCanada, Indonesia, Vietnam
-
Centre Hospitalier Universitaire, AmiensTerminatedAcute Respiratory Distress SyndromeFrance
-
Pontificia Universidad Catolica de ChileSociedad Chilena de PediatríaUnknownRespiratory Distress SyndromeChile
-
Windtree TherapeuticsCompletedAcute Hypoxemic Respiratory FailureUnited States, Chile
-
CTI BioPharmaCovanceCompleted
-
Austin HealthCompletedHypersensitivity, Immediate | Hypersensitivity, Delayed | Hypersensitivity ResponseUnited States, Australia, Canada
-
Gangnam Severance HospitalCompletedAcinetobacter Infections | Colistin | Rifampin
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineCompletedStaphylococcus AureusUnited States
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical UniversityRecruitingPreterm Birth | Acute Respiratory Distress Syndrome | Respiratory Distress Syndrome | Surfactant DysfunctionChina